BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $98.00

BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by Wells Fargo & Company from $88.00 to $98.00 in a report issued on Friday,Benzinga reports. The firm currently has an overweight rating on the stock.

Other analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of BridgeBio Pharma in a research note on Monday, November 3rd. TD Cowen reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, January 12th. The Goldman Sachs Group lifted their price objective on shares of BridgeBio Pharma from $55.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Barclays started coverage on shares of BridgeBio Pharma in a research note on Wednesday, January 28th. They issued an “overweight” rating on the stock. Finally, Cantor Fitzgerald lifted their price target on shares of BridgeBio Pharma from $100.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. Twenty-two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, BridgeBio Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.55.

BridgeBio Pharma Price Performance

Shares of NASDAQ:BBIO opened at $75.25 on Friday. The firm has a market capitalization of $14.50 billion, a PE ratio of -18.00 and a beta of 1.13. The business has a 50 day simple moving average of $75.60 and a two-hundred day simple moving average of $63.32. BridgeBio Pharma has a 1 year low of $28.33 and a 1 year high of $84.94.

Insider Transactions at BridgeBio Pharma

In related news, Director Andrew Lo sold 55,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $65.69, for a total value of $3,612,950.00. Following the completion of the transaction, the director owned 50,583 shares of the company’s stock, valued at $3,322,797.27. The trade was a 52.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Neil Kumar sold 40,000 shares of the company’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $71.94, for a total value of $2,877,600.00. Following the sale, the chief executive officer owned 695,686 shares of the company’s stock, valued at approximately $50,047,650.84. This represents a 5.44% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 233,167 shares of company stock valued at $16,536,002. Company insiders own 18.20% of the company’s stock.

Institutional Investors Weigh In On BridgeBio Pharma

Institutional investors have recently added to or reduced their stakes in the stock. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of BridgeBio Pharma during the second quarter valued at about $25,000. Aster Capital Management DIFC Ltd purchased a new stake in BridgeBio Pharma during the third quarter valued at approximately $31,000. Harvest Fund Management Co. Ltd acquired a new stake in BridgeBio Pharma in the third quarter valued at approximately $34,000. Jones Financial Companies Lllp acquired a new stake in BridgeBio Pharma in the first quarter valued at approximately $35,000. Finally, First Horizon Corp purchased a new position in BridgeBio Pharma in the third quarter worth $36,000. Institutional investors own 99.85% of the company’s stock.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: PROPEL 3 Phase‑3 topline: infigratinib met the primary endpoint (annualized height velocity) with a meaningful treatment difference vs. placebo, reported favorable safety, and BridgeBio plans NDA/MAA submissions in H2 2026 — a major de‑risking and commercialization step that drove earlier buying interest. Read More.
• Positive Sentiment: Analyst upgrades/target bumps: Wells Fargo raised its target to $98 (overweight) and Oppenheimer lifted its target to $83 (outperform). Those upgrades reinforced the commercial/regulatory narrative and supported the rally earlier in the week. Read More. Read More.
• Positive Sentiment: Competitive impact: BridgeBio’s positive data pressured rival programs (reports note BioMarin and Ascendis shares fell), suggesting BridgeBio may gain market share if approvals follow. Read More.
• Neutral Sentiment: Short‑interest reporting shows zero shares (likely a data or reporting glitch) and is not informative for positioning; ignore that metric until corrected by exchanges/data vendors.
• Negative Sentiment: Insider selling: CEO Neil Kumar sold 40,000 shares on Feb 10 (~$2.88M), part of a pattern of recent sales. That can prompt profit‑taking or investor concern about insider conviction despite large remaining holdings. Read More.
• Negative Sentiment: Near‑term financials remain a risk: Zacks flagged likely negative earnings in the upcoming report, keeping short‑term P&L and cash‑burn concerns on the table despite the clinical win. Read More.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.